RT info:eu-repo/semantics/article
T1 Predictors of clinically significant quality of life impairment in Parkinson’s disease
A1 Santos García, Diego
A1 Deus-Fonticoba, Teresa de
A1 Cores Bartolomé, Carlos
A1 Muñoz, Guillermo
A1 Paz González, José Manuel
A1 Martínez Miró, Cristina
A1 Suárez Castro, Ester
A1 Jesús, Silvia
A1 Aguilar, Miquel
A1 Pastor, Pau
A1 Planellás, Lluis L.
A1 Cosgaya, Marina
A1 García Caldentey, Juan
A1 Caballol, Núria
A1 Legarda, Inés
A1 Hernández Vara, Jorge
A1 Cabo López, Iria
A1 López Manzanares, Luis
A1 González Aramburu, Isabel
A1 López Manzanares, Luis
A1 González Aramburu, Isabel
A1 Ávila Rivera, María A.
A1 Catalán, María José
A1 Nogueira, Víctor
A1 Puente, Víctor
A1 Ruíz de Arcos, María
A1 Borrue, Carmen
A1 Solano Vila, Berta
A1 Álvarez Saúco, María
A1 Vela Desojo, Lydia
A1 Escalante Arroyo, Sonia
A1 Cubo Delgado, Esther
A1 Carrillo Padilla, Francisco
A1 Martínez Castrillo, Juan Carlos
A1 Sánchez Alonso, Pilar
A1 Alonso Losada, María Gema
A1 López Ariztegui, Nuria
A1 Gastón, Itziar
A1 Clavero Ibarra, Pedro
A1 Kulisevsky Bojarsky, Jaume
A1 Blázquez Estrada, Marta
A1 Seijo, Manuel
A1 Ruíz Martínez, Javier
A1 Valero, Caridad
A1 Kurtis, Mónica M.
A1 Fabregues, Oriol de
A1 González Ardura, Jessica
A1 Ordás Bandera, Carlos Manuel
A1 López Díaz, Luis M.
A1 McAfee, Darrian
A1 Martínez Martín, Pablo
A1 Mir, Pablo
A1 COPPADIS Study Group
K1 Sistema nervioso-Enfermedades
K1 Nervous system-Diseases
K1 Medicina
K1 Medicine
K1 Neurología
K1 Neurology
AB Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829–0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422–12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053–1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027–1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer–Lemeshow test, p = 0.665; R 2 = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663–17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975–22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.
PB Springer Nature
YR 2021
FD 2021-12
LK http://hdl.handle.net/10259/8806
UL http://hdl.handle.net/10259/8806
LA eng
DS Repositorio Institucional de la Universidad de Burgos
RD 24-nov-2024